Objective: To describe the effect of antiretroviral therapy (ART) and HIV-related factors on high-risk human papillomavirus (HR-HPV) and high-grade cervical intraepithelial neoplasia lesions (CIN2þ) among women living with HIV/AIDS (WLHA) in sub-Saharan Africa.
Introduction
Cervical cancer is the most common cancer among women in low-income and middle-income countries [1] , and one of the most common cancers in women living with HIV/AIDS (WLHA) [2] . Persistent infection with high-risk human papillomavirus (HR-HPV) genotypes is necessary for the development of squamous intraepithelial lesions (SIL) and cervical intraepithelial neoplasia (CIN) [3] . WLHA have higher prevalence of genital HR-HPV infection than the general population [4, 5] , are more likely to be infected with multiple high-risk types [6] , have persistent infection [7] , and have a higher risk of CIN progression [8] .
The interactions of antiretroviral therapy (ART) with HR-HPV and CIN are complex [9, 10] . ART increases potential exposure time to HR-HPV by decreasing mortality and increasing life expectancy of WLHA, allowing for accumulation of cellular genetic changes that increase the likelihood of cervical disease [11, 12] . Improved survival among WLHA may thus lead to increased cervical cancer rates [9] . Conversely, by decreasing HIV plasma viral load (PVL), ART can restore mucosal immune competence to help clear HR-HPV and reduce the incidence of precursor lesions [13, 14] . Some studies show that 'effective' ART (i.e., with high adherence, HIV viral suppression, and immune reconstitution) over longer durations decreases HR-HPV prevalence [13, 15, 16] , by decreasing incidence [17, 18] and promoting clearance [13, 17, 19] . ART has also been shown to reduce high-grade cytological squamous intraepithelial lesion incidence [20] and progression [21, 22] especially among adherent users [17] and those with sustained HIV viral suppression [23] . However, other studies have reported no such benefits of ART on HR-HPV [24, 25] or histological lesions [15, [26] [27] [28] [29] [30] , with some reporting a significant increased risk of highgrade cervical intraepithelial neoplasia lesions (CIN2þ) among ART users [31] .
Few longitudinal studies have reported the effect of ART and other HIV-related factors on the combined natural history of HR-HPV infection and histological cervical lesions. An improved understanding of the effects of ART, virological control, and immune recovery on the natural history of HR-HPV infection and CIN progression would help tailor screening guidelines for highrisk populations.
We conducted a study of cervical cancer screening in a cohort of WLHA in Burkina Faso (BF) and South Africa (SA; HARP -HPV in Africa Research Partnership). In this article, we describe the prevalence and persistence of HR-HPV infection; the prevalence and incidence of CIN2þ; and the associations of these outcomes with ARTand HIV-related factors (CD4 þ cell count and HIV-1 PVL).
Materials and methods

Study population
Participants were recruited from the HIVoutpatient clinic of the University Teaching Hospital of Ouagadougou, BF, and HIV treatment centers and surrounding communities in Johannesburg, SA from December 2011 to October 2012. Inclusion criteria were being HIV-1-seropositive, aged 25-50 years, and resident in the city. Exclusion criteria were history of prior treatment for cervical cancer, previous hysterectomy, and being pregnant or less than 8 weeks postpartum. Enrolment was stratified in a 2 : 1 ratio of ART-users:naïve. At enrolment, eligibility for ART initiation in both countries followed the 2010 WHO guidelines with a CD4 þ cell count threshold of 350 cells/ml [32] . Written informed consent was obtained at the screening visit when eligibility for the study was assessed and at enrolment. Data on clinical, sociodemographic and behavioral characteristics were collected by interviewer-administered questionnaire. Participants were followed up every 6 months for CD4 þ cell counts up to month 18 (endline) when procedures similar to baseline were repeated.
Specimen collection
At enrolment, a venous blood sample was collected to confirm HIV-1 serostatus if needed, to perform HSV-2 and syphilis serologies and to obtain baseline HIV-1 RNA PVL and CD4 þ cell counts. Urine pregnancy testing was performed. Cervical samples were collected using a Digene cervical sampler (Qiagen, Courtaboeuf, France) for HPV-DNA testing and genotyping; a cytobrush for Papanicolaou smear cytology; and a swab from the ecto/ endocervix to detect cervical sexually transmitted infections (STIs) by molecular methods. A vaginal smear was collected to diagnose bacterial vaginosis and Candida albicans by Gram stain. Participants were assessed clinically using visual inspection with acetic acid or Lugol's iodine (VIA/VILI). All participants were referred for colposcopy performed by trained colposcopists. Systematic 4-quadrant cervical biopsy, including directed biopsy of any suspicious lesions, was performed for participants who had abnormalities detected by cytology, VIA/VILI or colposcopy, or who were HR-HPV DNA-positive (Digene HC-II). The same genital sampling and examination procedures were repeated at the endline visit at month 18.
Laboratory testing HIV-1 serostatus was diagnosed according to national guidelines [33, 34] . Herpes simplex virus-2 serology was performed using the Kalon IgG2 ELISA (Kalon Diagnostics, Guildford, UK) and syphilis serology by a combination of a Treponema pallidum hemagglutination (TPHA) and rapid plasma reagin (RPR; BioMérieux, Lyon, France in BF; Immutrep carbon antigen RPR, Omega Diagnostics, Cape Town, South Africa in SA). Plasma HIV-1 RNA was assessed using real-time PCR (Abbott RT HIV-1) in BF and COBAS Taqman (Roche Diagnostics, Johannesburg, South Africa) in SA, with a lower limit of detection of 40 copies/ml. Testing for CD4 þ T-lymphocytes was performed using FACScount (Becton-Dickinson, Franklin Lakes, New Jersey, USA). Laboratories subscribed to international external quality assessment schemes; UK-National External Quality Assessment Service for CD4 þ cell counts [35] and Quality Control for Molecular Diagnostics for HIV-1 PVL testing [36] .
Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis were detected using nucleic acid amplification tests, the Sacace simplex assays (Sacace, Como, Italy) in BF and the APTIMA Combo (Gen-Probe, San Diego, California, USA) in SA. The Nugent's score [37] was used for vaginal flora reading of Gram-stained vaginal smears, with diagnosis of bacterial vaginosis made for scores at least 7, and examined for the presence of Candida spp.
HR-HPV testing was performed at the University of Montpellier virology laboratory using the qualitative Digene HC-II (Qiagen, Gaithersburg, Maryland, USA) and genotyping with the INNO-LiPA HPV genotyping Extra assay (Innogenetics, Courtaboeuf, France) [38, 39] . HR-HPV types were defined using the current International Agency for Research on Cancer (IARC) classification [40] : 'carcinogenic to humans' (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 ) and 'probable carcinogenic' (HPV68).
Cervical biopsies were processed at the local pathology laboratories in Ouagaoudou and Johannesburg and read using the three-tier CIN classification system [41] . Histology was classified as 'negative' ( CIN1) or 'positive' (CIN2þ) based on the highest reading across all findings from the four-quadrant biopsies and endocervical curettage if collected. All histological slides from women with a local diagnosis of CIN2þ and approximately 10% of slides from women with CIN1 or less histological findings were reviewed by the HARP Endpoint Committee of five pathologists, for consensus classification.
Statistical analysis HR-HPV type-specific persistence was defined as being positive for the same type at baseline and endline by genotyping. Type-specific clearance was defined as being positive for a specific HR type at baseline and negative for the same type at endline, whereas complete clearance was defined as being positive for at least one HR type at baseline and negative for all HR types at endline. As HR-HPV prevalence was common, associations with exposure variables were estimated with prevalence ratios obtained from logistic regression using marginal standardization to estimate prevalence ratios, and the delta method to estimate 95% confidence intervals (CIs) [42] .
Associations between HR-HPV persistence and exposure variables were estimated with generalized estimating equation to account for multiple HR-HPV infection and multiple infection states (persistence and clearance) [43] . For associations with CIN2þ prevalence and incidence for 16 months, logistic regression was used to estimate odds ratios (ORs) and 95% CI.
Multivariable analyses were adjusted for site and sociodemographic and behavioral factors that were independently associated in univariate analyses (P < 0.10) with HR-HPV or CIN2þ for each country (Model 1). To explore associations of HR-HPV and CIN2þ outcomes with HIV-related factors, prespecified analyses included stratification by site, ARTuse and duration ( or >2 years), HIV-1 viral suppression (< or !1000 copies/ ml) and CD4 þ cell counts. Stable high CD4 þ cell count was defined as having CD4 þ cell counts more than 500 cells/ml at baseline, month 12, and endline visits. A second logistic regression model (Model 2) incorporated baseline CD4
þ cell count to Model 1 to explore associations with ART. Data were analyzed using Stata version 14 (Stata Statistical Software; Stata Corporation, College Station, Texas, USA). 
Results
Study population
Of 1473 women screened, 1238 were enrolled (BF: 615; SA: 623; Fig. 1 ). The median age of participants was 36 [interquartile range (IQR), [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] years in BF and 34 (IQR, (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) years in SA (Table 1 ). Participants in BF had lower levels of education and were less likely to be employed than those in SA. Classical risk factors for HR-HPV and CIN, including smoking, hormonal contraception use, and higher number of sexual partners, were more prevalent in SA than BF, as were all STIs, except Candida infection. About half (49.6%) of SA participants had ever had a Pap smear, and one-fifth (20.8%) of BF participants had ever had a VIA/VILI examination, the primary cervical cancer screening modality in each country, respectively.
At enrolment, 422 (68.6%) participants were on ART in BF and 406 (65.2%) in SA, reflecting the 2 : 1 stratification ratio. There were 126 women in BF and 22 in SA who initiated ART in the month prior to enrolment. The median duration on ARTwas 17 (IQR, 0-63) months in BF and 28 (IQR, 10-50) months in SA. The median CD4 þ cell count among ART-naive and ART users was 417 (IQR, 315-606) cells/ml and 446 (IQR, 309-600) cells/ml, respectively, in BF and 448 (IQR, 353-614) cells/ml and 420 (IQR, 279-567) cells/ml in SA. HIV-1 RNA was undetectable ( 40 copies/ml) in 69.9 and 33.7% of ART users in BF and SA, respectively, whereas HIV-1 RNA suppression (<1000 copies/ml) was 79.9 and 80.3% among ART users in BF and SA, respectively. Overall, 32 participants (BF: 24; SA: 8; 2.6%) denied being on ART at enrolment despite undetectable HIV-1 PVL. Of these, 23 (72%) had CD4 þ cell count more than 500 cells/ml. Given the uncertainty of their status, these women were excluded from HIV-related factors analyses.
Of the 1077 women without CIN2þ at baseline, 963 (89.4%) were seen at endline visit (median follow-up 16 months, IQR, 15.6-16.8). Fifty-three women (10.4%) in BF and 25 (5.5%) in SA initiated ART during follow-up ( Table 2 ). The median CD4 þ cell count changes among ARTusers at baseline, ART initiators and those who remained ART-naive were þ105, þ123, and þ65 cells/ml per year, respectively, in BF, and þ5, þ83, and À53 cells/ml per year, respectively, in SA. HR-HPV prevalence was higher among those with low CD4 þ cell count in both countries (Table 3 ) and this association was strongest among ART users [CD4 þ cell count <200 vs. >500 cells/ml, adjusted prevalence ratio (aPR) ¼ 1.30, 95% CI 1.13-1.49, adjusted for site].
Compared with long-duration ART users (>2 years), HR-HPV prevalence was higher among those on shortduration ART in both countries ( 2 years); however, when adjusted for CD4 þ cell count, this association was observed in BF only (65.1 vs. 52.1% for 2 years compared with >2 years; aPR ¼ 1.24, 95% CI 1.04-1.47, Table 3 ). There was weak evidence of higher HR-HPV prevalence among ART-naive compared with long-term ART users in both countries (Table 3) .
Association of high-risk human papillomavirus persistence with antiretroviral therapy and HIV-related factors Among 610 women without CIN2þ but HR-HPVpositive at baseline, the total number of baseline infections was 1028 (BF: 416; SA: 612; Table 2 ). Persistent infection of an HR-HPV type at endline was slightly higher in BF (BF: 41.1% vs. SA: 30.2%; P < 0.001, Table 2 ).
HR-HPV persistence was associated with low baseline CD4 þ cell count in BF only and this association was strongest among ART users (CD4 þ cell count <200 vs. >500 cells/ml, aOR ¼ 1.85, 95% CI 1.15-2.96, Model 1, Table 4 ). HR-HPV persistence was higher among ART-naive compared with long-duration ART users in both sites (Model 1, Table 4 ). However, when adjusted for baseline CD4 þ cell count (Model 2, Table 4 ), the association persisted in BF only (58.6 vs. 37.7%; aOR ¼ 1.89, 95% CI 1.26-2.83). In SA, HR-HPV persistence was higher among short-duration compared with long-duration ART users even after adjustment (aOR ¼ 1.78, 95% CI 1.11-2.86; Model 2, Table 4 ). Association of cervical intraepithelial neoplasia lesion prevalence and incidence with antiretroviral therapy and HIV-related factors CIN2þ prevalence was higher among participants with low baseline CD4 þ cell count in both countries (Table 3 ; combined effect: CD4 þ cell count <200 vs. The study was designed to include two-thirds of participants on ART in each site. g Data on self-reported adherence were unavailable for 24 participants in BF and four in SA. Table 4 . Effect of HIV-related factors on high-risk human papillomavirus persistence, using infections as unit of measure. >500 cells/ml, aOR ¼ 3. CIN2þ prevalence was higher among participants on short-duration ART ( 2 years) and among ART-naive compared to long-duration ART users in SA and these associations persisted after adjustment for baseline CD4 þ cell count (ART 2 years vs. >2 years: aOR ¼ 1.99, 95% CI 1.12-3.54; ART-naive vs. ART >2 years: aOR ¼ 1.87, 95% CI 1.11-3.17, Table 3 ).
The incidence of CIN2þ for 16 months was higher in SA [BF: 1.2% (5/430) vs. SA: 5.8% (22/379); P < 0.001; Table 2 ]. There was weak evidence that CIN2þ incidence was lower among consistent ART users (i.e. on ARTat both baseline and endline visit) compared with those who remained ART-naive in SA (4.4 vs. 9.9%; aOR ¼ 0.39, 95% CI 0.15-1.01, adjusted for number of lifetime sex partners and baseline CD4 þ cell count), but no association was observed in BF due to the small number of incident cases.
Association of cervical intraepithelial neoplasia lesions with high-risk human papillomavirus Among 1119 women with genotyping and histology data at enrolment, prevalence of CIN2þ was significantly higher among those HR-HPV-positive compared with HR-HPV-negative (BF: 9.8 vs. 0.0%; SA: 25.7 vs. 10.2%; aOR ¼ 5.12, 95% CI 2.66-9.89, adjusted for site, CD4 þ , and ART). Among 780 women with genotyping and histology at baseline and endline, CIN2þ incidence for 16 months was higher among those with HR-HPV persistence compared with those who had type-specific clearance or who were HR-HPV-negative at baseline (BF: 3. 
Discussion
This large prospective study found high prevalence and persistence of HR-HPVamong women living with HIV-1 in BF and SA, and HR-HPV persistence was associated with incidence of CIN2þ for 16 months. Strikingly, CIN2þ prevalence and incidence were higher in SA despite balanced distribution of ART use, similar median duration on ART and median CD4 þ cell counts at study enrolment in both countries, and similar HR-HPV persistence rates for 16 months.
We found that low baseline CD4 þ cell count was associated with a higher prevalence of HR-HPV and CIN2þ in both countries, and with HR-HPV persistence in BF, similar to other studies that have shown CD4
þ cell count to be one of the strongest predictors of HR-HPV infection [44] and cervical lesion development [45] . We also found that prolonged duration of ART was associated with lower CIN2þ prevalence and HR-HPV persistence, similar to others [13, 15, 46] , and this association was independent of baseline CD4 þ cell count. Although HR-HPV persistence was similar in both countries, cervical lesion progression was higher in SA and this may have been influenced by the role of HIV-related and other cofactors, which differed between the two countries.
In BF, prolonged and short-duration ART users had a similar risk of HR-HPV persistence when CD4 þ cell counts were more than 500 cells/ml. However, the risk was higher among short-duration compared with longduration ART users when CD4 þ cell count was low (<200 cells/ml). This suggests that once the recent ART initiators begin to recover CD4 þ T lymphocytes, they can control HR-HPV persistence, leading to the lower prevalence of CIN2þ.
By contrast, in SA, short-duration ART users had higher persistence of HR-HPV and CIN2þ prevalence, irrespective of baseline CD4 þ cell count. This may be a consequence of several factors. First, ART users in SA were not as well HIV-controlled as their counterparts in BF. Effective ART use, as measured by HIV-1 RNA suppression (PVL <1000 copies/ml), was associated with a decrease in HR-HPV persistence for 16 months in SA, independent of baseline CD4 þ cell count. Others have shown that HR-HPV persistence was increased two to three-fold among women (6% ART users) with detectable genital tract HIV RNA levels, after adjusting for CD4 þ cell count but not when adjusted for plasma HIV [47] , thereby suggesting a possible direct role of HIV on HR-HPV through both local and systemic mechanisms. The greater proportion of ART users in SA with detectable HIV PVL (65% in SA vs. 23% in BF) may be a consequence of their poor self-reported adherence, which was observed among both short-duration and long-duration ART users. Women with suboptimal adherence may have developed, or initially acquired, some antiretroviral-resistant HIV strain, although we cannot verify this in the absence of HIV genotyping. Second, ART use in the short-term may be ineffective in clearing HR-HPV if already well established. Others have shown that ARTusers are at a higher risk for cervical disease if they have initiated ART at a lower nadir CD4 þ cell count [27, 48, 49] . In such cases, the CD4 þ Tlymphocyte reconstitution accompanying ART may be partial or functionally impaired and the beneficial effects of ART may only become apparent after long treatment periods [12] . It is possible in our study that immune reconstitution achieved through recent ART initiation at the previous WHO cutoff of 350 cells/ml may have been insufficient to prevent HR-HPV persistence and/or CIN2þ development, in particular when coupled with detectable HIV, lower ART adherence and lower CD4 þ T-lymphocyte recovery over time, as was the case among women in SA. Early ART initiation, coupled with rapid virological control, is likely to rapidly improve and maintain CD4
þ cell count at a higher level [50] , leading to possibly more complete and sustained immune reconstitution, thereby reducing the risk of persistent HR-HPV and cervical lesion development. Finally, the higher CIN2þ prevalence and incidence in SA may additionally be explained by other cofactors for such as greater frequency of contraceptive use and smoking and higher prevalence of mucosal STIs [51] [52] [53] . The presence of STIs can trigger genital HIV replication, a cascade of mucosal immunological synergies, and vaginal biome changes [54, 55] , which may interact with HR-HPV [56] . Addressing such cofactors should also be a priority of cervical cancer prevention programs.
Importantly, this study has found that ART use was associated with a reduction in incident CIN2þ for 16 months in SA. Furthermore, by endline, ART duration had increased to a median 44 months, which may have played a role in averting CIN development.
ART-naive women in SA had similar HR-HPV persistence and CIN2þ prevalence as prolonged ART users at high CD4 þ (>500 cells/ml), but both outcomes worsened among the ART-naive as CD4 þ cell count decreased. This finding highlights the role of early ART initiation to favorably influence the natural history of HR-HPV and CIN. This study was constrained by the absence of consistent data on nadir CD4 þ cell count, absence of a HIV-1 PVL measure at the endline visit, and the limited number of intermediate visits and overall follow-up duration. Despite these limitations, this study had several strengths, including its longitudinal design, the availability of a rigorously validated histological endpoint for the majority of women, thereby minimizing disease ascertainment bias; and the availability of genotyping data at both time points. Moreover, the HARP study was undertaken in two countries with different HIV epidemics, burdens of HPV infection and cervical cancer, and approaches to screening for cervical cancer. This allows the findings to be extended to a range of countries and settings in the region.
In conclusion, this study confirms that women living with HIV-1 in sub-Saharan Africa have extraordinarily high rates of HR-HPV infection and CIN2þ. Effective ART use for prolonged duration is essential in reducing HR-HPV persistence and CIN2þ incidence. Early ART initiation is likely to further reduce the risk of HR-HPV infection and incident cervical lesions. These data underscore the importance of cervical cancer screening and access to treatment in these highly exposed and vulnerable populations, and the need for close monitoring of both HIV-related and HPV/CIN parameters before or during ART treatment as part of a comprehensive cervical cancer prevention program.
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